Die Lieblings-Investments der Deutschen - Auf welche Anlagen Sparer in einer Welt ohne Zinsen setzen - und was das langfristig bedeutet.-w-

Merck Aktie WKN: 659990 / ISIN: DE0006599905

143,15EUR
-1,35EUR
-0,93%
17:02:17
Diese Aktie kaufen
Werbung

Merck Aktien News

16.03.21Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer (PR Newswire)
16.03.21Merck Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer (PR Newswire)
25.02.21New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients Mount Protective Antibody Response to Common Vaccines (PR Newswire)
27.11.20European Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations (PR Newswire)
09.11.20Merck Announces Out-Licensing Agreement for Investigational Atacicept with Vera Therapeutics (PR Newswire)
06.10.20Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis (PR Newswire)
14.09.20Merck Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020 (PR Newswire)
11.09.20New MAVENCLAD® Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting Highlight Rapid Onset of Action and Compelling Post-Approval Safety (PR Newswire)
10.09.20Merck Announces Positive Phase II Results for Investigational Sonelokinab (M1095) in Patients with Moderate to Severe Chronic Plaque-Type Psoriasis (PR Newswire)
03.09.20Merck to Showcase New Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting, Furthering Innovation in Multiple Sclerosis (PR Newswire)
13.07.20Stephan Sieber Awarded € 1 Million Future Insight Prize 2020 by Merck (PR Newswire)
28.05.20Merck and Twitch Join Forces on World Multiple Sclerosis Day to Connect People Living With MS (PR Newswire)
19.05.20Merck Foundation Announce 'Stay at Home' Media Recognition Awards for Latin American Countries (PR Newswire)
14.05.20/C O R R E C T I O N -- EMD Serono/ (PR Newswire)
14.05.20Breakthrough Innovation in Cancer Care From Merck Pipeline to Be Presented at ASCO 2020 (PR Newswire)
14.05.20Breakthrough Innovation in Cancer Care From EMD Serono Pipeline to Be Presented at ASCO 2020 (PR Newswire)
30.04.20Data From Merck at ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care (PR Newswire)
03.03.20/DISREGARD RELEASE: Merck KGaA, Darmstadt, Germany/ (PR Newswire)
02.03.20ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) (PR Newswire)
02.03.20ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) (PR Newswire)
20.11.19Merck KGaA, Darmstadt, Germany, Announces Orphan Drug Designation for Investigational Therapy Tepotinib in Patients with NSCLC Harboring MET Gene Alterations (PR Newswire)
28.10.19European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma (PR Newswire)
27.09.19New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019 (PR Newswire)
23.09.19New Data at ESMO 2019 for Merck KGaA, Darmstadt, Germany, Highlight Focused Clinical Development and Commitment to Patient Care (PR Newswire)
23.09.19New Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Care (PR Newswire)
20.09.19CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma (PR Newswire)
11.09.19Merck KGaA, Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations (PR Newswire)
11.09.19Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations (PR Newswire)
09.09.19Updated Results for Investigational Therapy Tepotinib Presented at WCLC 2019 (PR Newswire)
22.07.19DGAP-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
03.06.19Merck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations (PR Newswire)
03.06.19Merck KGaA, Darmstadt, Germany Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations (PR Newswire)
16.05.19DGAP-DD: Merck KGaA english (EQS Group)
15.05.19DGAP-DD: Merck KGaA english (EQS Group)
25.04.19DGAP-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
27.02.19DGAP-Adhoc: Merck KGaA: Merck Proposes to Acquire Versum for USD 48 per Share and to Create a Leading Electronic Materials Player (EQS Group)
25.02.19DGAP-AFR: Merck KGaA: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] (EQS Group)
25.02.19DGAP-AFR: Merck KGaA: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements (EQS Group)
05.02.19DGAP-Adhoc: Merck KGaA: Merck and GSK agree on Collaboration in Immuno-Oncology (EQS Group)
24.01.19Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors (PR Newswire)
Seite: 12345

Merck News

Merck News: auf dieser Seite finden Sie alle Merck News und Nachrichten zur Merck Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Merck News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Merck News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.
Werbung

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln